Provider review
Polly Review: The 21.5% Headline Is Gone, and So Is the Disclaimer Under It
On 14 August this review was about one sentence: “Lose up to 21.5% body weight”, a branded tirzepatide trial's ceiling attached to a page selling compounded semaglutide. Re-read on 26 August, the site has been rebuilt on a new domain and that sentence is gone. So is the disclaimer that used to sit beneath it, naming Mounjaro, Zepbound, Wegovy and Ozempic and saying Polly's products are not substitutes for them. What is left is a flat price grid, two named pharmacies, and no comparison to the trials in either direction.
Correction, August 2026
This review previously said: “Polly headlines “up to 21.5% body weight” for a compounded GLP-1 — a branded drug's best-case trial result its own disclaimer disowns.”
That was wrong. This was accurate when it was published on 14 August, and it is recorded here rather than quietly deleted because a reader who saw the page then needs to know it no longer describes the site. Between then and 26 August the company completed its move from joinpiper.com to joinpolly.com and rebuilt the site, and the sentence went with the old build. We are not claiming credit for the change and have no evidence about why it was made.
It now says: Neither the 21.5% headline nor the disclaimer under it appears anywhere on joinpolly.com — checked on the home page, the rebrand notice and the terms. The claim grade on the semaglutide row moves from `overstates` to `matches`, because what is there now is a description with no number in it. Two things went the other way. The disclaimer that named Mounjaro, Zepbound, Wegovy and Ozempic and said Polly's products are not substitutes for them has also gone, and nothing now tells a reader that the trial evidence belongs to the approved drugs. On the other side of the ledger, the rebuilt site names two compounding pharmacies, states the 503A category and publishes fifty-state coverage, none of which the old one did.
Rebuilt as Polly on a new domain, and the rebuild took the 21.5% headline out along with the disclaimer that contradicted it. What replaced them is a flat price grid, two named pharmacies and a stated 503A category — a better page, with the trial comparison now made nowhere at all.
Worth trusting if
- You want a plain flat price you can read before answering anything — six products, one figure each, same price at every dose
- You want the pharmacy named, because Polly now names Hallandale and VialsRx and states the 503A category
- You want a seller that has stopped quoting a trial number it could not support
Be skeptical if
- You need to know the plan length before you pay — the grid shows none, and the six-month plan surfaces only in the refund policy
- You may want to stop mid-term, because refunds are not prorated within a billing cycle and are unavailable once the prescription has gone to the pharmacy
- You want the company's name, domain and entity to agree, which after the Piper-to-Polly move they still do not
Compounded only
Phase 3 trials
Named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.joinpolly.com. A link is not a recommendation to take anything.
Provenance
What Polly (formerly Piper) actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — $135/mo, one flat figure with "Same price for every dose" and "No membership or hidden fees" beside it, public before any question. The other five products are priced the same way: tirzepatide $199, sermorelin $179, NAD+ spray $199, NAD+ vial $183, lipotropic MIC with B12 $99. The $50 on the home page is a referral credit, not a discount. Re-read 2026-08-26 with one correction to the earlier note: a term does exist, it is just not on the price grid. The refund policy says "If you are on a 6-month plan and have 3 or more months remaining, cancellations are not automatically eligible for a refund", so six-month plans are sold somewhere past the grid, and the terms describe an automatically renewing subscription.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
1
Molecules with human evidence
For the use they are sold for, out of 1 products reviewed here. The evidence belongs to the molecule, not to Polly (formerly Piper).
2
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Polly (formerly Piper)’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)Claim matches the trials
“Lose up to 21.5% body weight¹ […] They are not intended to diagnose, treat, cure, or prevent any disease and are not substitutes for FDA-approved medications such as MOUNJARO®, ZEPBOUND™, Wegovy®, or Ozempic®.”
Read on the Polly (formerly Piper) site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tirzepatide over 72 weeks; roughly 20–22% mean reduction at the highest tolerated dose. This is the trial the 21.5% figure comes from — and it is tirzepatide, not the semaglutide Polly prices on this page.
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — roughly 14.9% mean weight loss, which is the figure that actually corresponds to the molecule on this page.
This row was graded `overstates` on 2026-08-14 and is re-graded here on 2026-08-26, because the claim it was about is no longer on the site — see the correction at the top of the page. The 21.5% headline was a top-of-range TIRZEPATIDE result from SURMOUNT-1 at the highest tolerated dose, attached to a page selling compounded semaglutide, whose own trial figure is around 14.9%. Neither that sentence nor the disclaimer that sat under it appears anywhere on joinpolly.com today. What Polly says about compounded semaglutide now is "Supports metabolism, energy, and weight loss" — a description with no number, no timeline and no trial behind it, which is nothing to grade against. Two things are worth keeping in view. The disclaimer that named Mounjaro, Zepbound, Wegovy and Ozempic and said Polly's products are not substitutes for them has gone too, and it was the more useful of the two sentences. And the trial evidence a reader arrives with belongs to the approved products, not to a compounded preparation, which the current site does not say either way.1,2
Dispensing chain
Who actually fills your prescription
- Hallandale Pharmacy
- VialsRx
Read the full account
Re-checked 2026-08-26 and this has changed for the better. Polly now names pharmacies and states the category: "Polly partners with licensed 503A compounding pharmacies across the United States, including pharmacies such as Hallandale Pharmacy and VialsRx. These pharmacies are overseen by State Boards of Pharmacy." State boards are the correct authority, and 503A is the correct category. Two limits on how far that gets a reader: "such as" means the list is partial rather than complete, and no address, license number or link is given for either pharmacy. This review previously recorded that no pharmacy was named at all.
Read on the Polly (formerly Piper) site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency result or purity result is published or offered, and no pharmacy is named who could be asked for one.
Read on the Polly (formerly Piper) site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
Re-checked 2026-08-26: it now answers this, and this review previously said it did not. "Polly facilitates access to independent licensed providers and partner pharmacies available in all 50 U.S. states. We connect you with healthcare professionals and pharmacies that are fully licensed to practice and dispense in your specific state." No exclusions are named.
Read the full licensing claim
"Independent licensed providers" facilitated through the platform, with dispensing by licensed 503A compounding pharmacies "overseen by State Boards of Pharmacy". No individual clinician is named.
Read on the Polly (formerly Piper) site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Polly (formerly Piper)
We went through Polly (formerly Piper)’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Every price is on the home page grid before anything is asked. Press "Get started" on one.
- The visit opens on app.joinpolly.com and asks for an email address.
- "Create an account" — first name, last name, and a password of at least eight characters with an uppercase letter, a number and a symbol, plus a terms and telehealth consent box.
- This walk stopped there. We do not create password-protected accounts, so nothing past that screen was seen.
- Six treatments are priced on one grid before any question: compounded semaglutide $135, compounded tirzepatide $199, sermorelin $179, NAD+ spray $199, NAD+ vial $183, lipotropic MIC with B12 $99.
- Each is a single flat figure, with "Same price for every dose" and "No membership or hidden fees" printed above the grid. No plan lengths and no struck-through anchors appear anywhere on it.
- A six-month plan exists all the same, and the only place it appears is the refund policy: "If you are on a 6-month plan and have 3 or more months remaining, cancellations are not automatically eligible for a refund."
- The terms describe an automatically renewing subscription, and the refund policy adds that partial or prorated refunds are not offered for unused time within a billing cycle, and that no refund is issued once the prescription has gone to the pharmacy.
- joinpiper.com now redirects to joinpolly.com, and the footer entity is "Piper Wellness LLC d/b/a JoinPolly". Both names still matter if you are checking a license or a complaint record.
- The home page names its pharmacies — Hallandale Pharmacy and VialsRx — as licensed 503A compounders "overseen by State Boards of Pharmacy", and says the list is "such as" rather than complete.
- The visit demands a password-protected account at its second screen, before a single medical question.
Polly (formerly Piper) support
- care@joinpolly.com
Assessment
What holds up, and what does not
- The 21.5% headline this review was written about is gone from the rebuilt site, and nothing has replaced it — the current product line reads as descriptions rather than promises.
- It names two of its compounding pharmacies, Hallandale and VialsRx, and states the category as 503A overseen by State Boards of Pharmacy, which is the correct authority.
- It publishes its state coverage: all fifty.
Show 2 more
- The operating entity is published: Piper Wellness LLC, trading as JoinPolly.
- Six treatments carry a flat figure each, readable before any question, with the same price at every dose.
- The disclaimer went out with the headline. The site no longer says anywhere that its products are not substitutes for Mounjaro, Zepbound, Wegovy or Ozempic, and that was the most useful sentence on the old page.
- Nothing on the rebuilt site tells a reader that the trial evidence they arrive with belongs to the approved products rather than to a compounded preparation.
- The price grid publishes no plan length. A six-month plan exists and appears only in the refund policy.
Show 5 more
- Refunds are not prorated within a billing cycle, and none is available once the prescription has been sent to the pharmacy.
- The pharmacy list is "such as" rather than complete, and neither named pharmacy is given an address, a license number or a link.
- No certificate of analysis or test result is published.
- The rebrand is still half-finished: the entity is Piper Wellness LLC, the old domain redirects, and the home page still carries a "Most P4opular" typo above the price grid.
- The visit demands a password-protected account at the second screen, before any medical question.
Verdict
The bottom line
The number this review was written about is gone, and so is the disclaimer that used to sit under it — so bring your own: semaglutide's phase 3 mean is around 14.9%, that trial tested the approved product, and what Polly sells is compounded. On money, read the refund policy before the price grid. The grid shows no plan length; the refund policy is where the six-month plan turns up, and where you learn that unused time inside a billing cycle is not refunded.
Opens www.joinpolly.com. A link is not a recommendation to take anything.
The headline and the footnote
"Lose up to 21.5% body weight¹"
That number comes from SURMOUNT-1, a phase 3 trial of tirzepatide in 2,539 participants over 72 weeks. 1
Three things are wrong with its use here.
It is a ceiling, not an expectation. 21.5% is what participants achieved at the highest tolerated dose. "Up to" is technically correct and does the work of a hedge while the number does the work of a promise.
It is the wrong molecule. The page prices compounded semaglutide. Semaglutide's own phase 3 result, from STEP 1, is a mean of around 14.9%. 2 The tirzepatide figure is roughly 45% larger, and it is not what this product contains.
It is a trial of the approved drug. SURMOUNT-1 tested branded tirzepatide, manufactured to a registered specification. A compounded preparation is a different article.
Full analysis — 6 more sectionsThe sentence that contradicts it · What the site says now · Piper, Polly, and why the name matters · What each treatment costs · What is published now, and what is not · What this means if you are buying
The sentence that contradicts it
Elsewhere on the same site:
"They are not intended to diagnose, treat, cure, or prevent any disease and are not substitutes for FDA-approved medications such as MOUNJARO®, ZEPBOUND™, Wegovy®, or Ozempic®."
This is a good disclaimer. It names the specific drugs and states the specific limit.
It also directly contradicts the headline, which works only if the reader believes the compounded product will do what those drugs did in their trials. A site cannot both borrow a trial result and disown the comparison the borrowing depends on.
What the site says now
Re-read on 26 August 2026. Neither sentence above appears anywhere on joinpolly.com — not on the home page, not on the rebrand notice, not in the terms. The product line reads as descriptions instead: compounded semaglutide "supports metabolism, energy, and weight loss", compounded tirzepatide is a "dual-action treatment for weight loss and blood sugar control". No percentage, no timeline, no trial reference.
Removing an overstated number is the right move and is recorded as such. What went with it is worth naming too: the disclaimer was the more useful of the two sentences, and nothing on the rebuilt site now tells a reader that the trial evidence they arrived with belongs to Wegovy and Zepbound rather than to what ships in the vial.
Piper, Polly, and why the name matters
The page is titled "Join Polly (Formerly Join Piper)". joinpiper.com now redirects to joinpolly.com. The operating entity in the footer is Piper Wellness LLC d/b/a JoinPolly.
A company mid-rebrand is not suspicious in itself, but it is worth recording: checking a state license, a complaint history or a regulatory record requires knowing which name to search, and the answer is still both. The rebuild is not quite finished either — the price grid is headed "Most P4opular".
What each treatment costs
Six products, one figure each, all public before a single question:
- Compounded semaglutide — $135
- Compounded tirzepatide — $199
- Sermorelin — $179
- NAD+ spray — $199
- NAD+ vial — $183
- Lipotropic (MIC) + B12 — $99
Above them: "Same price for every dose. No membership or hidden fees." No plan lengths, no struck-through anchors, no starter rate. On a page-by-page comparison with the rest of this batch, that is the clearest price grid of the eight.
The part it does not show is the term. The refund policy is where that surfaces:
"If you are on a 6-month plan and have 3 or more months remaining, cancellations are not automatically eligible for a refund."
So six-month plans are sold. They are not on the grid. The same policy says partial or prorated refunds are not offered for unused time within a billing cycle, and that no refund is issued once the prescription has been sent to the pharmacy; the terms describe an automatically renewing subscription. Read that page before the price page.
What is published now, and what is not
Polly names pharmacies, which it did not before:
"Polly partners with licensed 503A compounding pharmacies across the United States, including pharmacies such as Hallandale Pharmacy and VialsRx. These pharmacies are overseen by State Boards of Pharmacy."
State boards are the right authority and 503A is the right category. "Such as" means the list is partial, and neither pharmacy is given an address, a license number or a link. It also publishes its coverage — all fifty states. Still absent: any certificate of analysis, potency result or purity result.
What this means if you are buying
If you want compounded semaglutide, the number to hold in your head is 14.9%, from a trial of the approved drug, with the compounded preparation an untested variation on it. 2 Polly no longer offers you a number at all, which is better than offering the wrong one and is not the same as telling you this.
Questions
Frequently asked questions
Can I expect to lose 21.5% of my body weight?
No. That figure is what tirzepatide achieved at the highest tolerated dose in the SURMOUNT-1 phase 3 trial — a top-of-range result, not a typical one. It is also a tirzepatide number, while the page it appears on prices compounded semaglutide, whose phase 3 mean is around 14.9%. And it comes from a trial of the FDA-approved branded drug rather than a compounded preparation.
Is Polly the same company as Piper?
Yes. Re-checked 26 August 2026: joinpiper.com now redirects to joinpolly.com, the page is still titled “Join Polly (Formerly Join Piper)”, and the footer entity reads “Piper Wellness LLC d/b/a JoinPolly”. Both names refer to the same company, which matters if you are checking a license or complaint record — search both.
Which pharmacy compounds the medication?
Polly does not say. The site states only that treatment ships “from a licensed pharmacy”, without naming it or stating whether it is a 503A or 503B facility, so nothing in the supply chain can be independently checked.
Compare
Others selling what Polly (formerly Piper) sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Polly (formerly Piper)'s own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.